Vera Therapeutics (NASDAQ:VERA) CEO Sells $1,010,991.55 in Stock

Vera Therapeutics, Inc. (NASDAQ:VERA) CEO Marshall Fordyce sold 22,951 shares of the business’s stock in a transaction that occurred on Tuesday, April 14th. The shares were sold at an average price of $44.05, for a total value of $1,010,991.55. Following the transaction, the chief executive officer owned 235,244 shares of the company’s stock, valued at $10,362,498.20. This represents a 8.89% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Marshall Fordyce also recently made the following trade(s):

• On Monday, February 23rd, Marshall Fordyce sold 16,925 shares of Vera Therapeutics stock. The shares were sold at an average price of $41.98, for a total value of $710,511.50.

Vera Therapeutics Stock Performance

NASDAQ:VERA traded down $0.91 during midday trading on Wednesday, reaching $43.45. 1,321,636 shares of the company traded hands, compared to its average volume of 1,187,074. Vera Therapeutics, Inc. has a twelve month low of $18.76 and a twelve month high of $56.05. The firm has a market capitalization of $3.10 billion, a price-to-earnings ratio of -9.32 and a beta of 1.17. The company has a debt-to-equity ratio of 0.12, a current ratio of 13.64 and a quick ratio of 13.64. The company has a fifty day moving average price of $41.18 and a 200 day moving average price of $39.46.

Vera Therapeutics (NASDAQ:VERA) last released its quarterly earnings data on Thursday, February 26th. The company reported ($1.39) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.34) by ($0.05). During the same quarter last year, the business posted ($0.72) earnings per share. On average, analysts expect that Vera Therapeutics, Inc. will post -2.89 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on VERA. HC Wainwright boosted their price target on Vera Therapeutics from $90.00 to $110.00 and gave the stock a “buy” rating in a research report on Monday, March 2nd. The Goldman Sachs Group boosted their price target on Vera Therapeutics from $55.00 to $95.00 and gave the stock a “buy” rating in a research report on Friday, December 19th. Bank of America boosted their price target on Vera Therapeutics from $48.00 to $66.00 and gave the stock a “buy” rating in a research report on Friday, December 19th. Wolfe Research upgraded Vera Therapeutics from a “peer perform” rating to an “outperform” rating and set a $88.00 price target for the company in a research report on Wednesday, March 11th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Vera Therapeutics in a research report on Wednesday, January 21st. Ten equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $81.45.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. GAMMA Investing LLC lifted its holdings in shares of Vera Therapeutics by 50.5% in the fourth quarter. GAMMA Investing LLC now owns 703 shares of the company’s stock valued at $36,000 after buying an additional 236 shares during the period. Los Angeles Capital Management LLC bought a new position in Vera Therapeutics during the fourth quarter valued at about $46,000. Quantbot Technologies LP acquired a new position in Vera Therapeutics during the second quarter worth about $51,000. Aster Capital Management DIFC Ltd acquired a new position in Vera Therapeutics during the fourth quarter worth about $71,000. Finally, Tower Research Capital LLC TRC grew its holdings in Vera Therapeutics by 192.9% during the second quarter. Tower Research Capital LLC TRC now owns 4,186 shares of the company’s stock worth $99,000 after acquiring an additional 2,757 shares during the period. Institutional investors and hedge funds own 99.21% of the company’s stock.

Vera Therapeutics Company Profile

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.